Quantbot Technologies LP Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Quantbot Technologies LP acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 25,454 shares of the company’s stock, valued at approximately $945,000. Quantbot Technologies LP owned 0.05% of Amphastar Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. TD Private Client Wealth LLC lifted its position in shares of Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after acquiring an additional 388 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares in the last quarter. KBC Group NV boosted its stake in Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the period. Finally, Sanctuary Advisors LLC grew its holdings in Amphastar Pharmaceuticals by 8.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after buying an additional 801 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 27.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st.

Amphastar Pharmaceuticals Trading Down 0.2 %

Amphastar Pharmaceuticals stock opened at $28.39 on Wednesday. The stock has a market cap of $1.35 billion, a P/E ratio of 9.46, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The firm’s fifty day moving average price is $31.52 and its 200-day moving average price is $40.24. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.